Achillion reports that it achieved threshold enrollment in the Phase 2 trials of ACH-4471 for patients with C3 glomerulopathy (C3G), a devastating disease affecting the kidney for which there is no approved therapy … more
Eralier, Achillion announced achievement of enrollment in their ACH-4471 Phase 2 paroxysmal nocturnal hemoglobinuria (PNH) trial in combination with eculizumab … more